section name header

Evidence summaries

Riluzole for Patients with ALS

Riluzole appears to somewhat extend the time to tracheostomy and death in patients with amyotrophic lateral sclerosis (ALS). It prolongs survival by about 3 months. Level of evidence: "B"

A Cochrane review [Abstract] 1 included 4 trials with 1477 patients with motoneuron disease. The trials examined tracheostomy-free survival. One trial (n=169) included older patients in more advanced stages of ALS. Riluzole 100 mg daily provided a benefit for the homogeneous group of patients in the first two trials (HR 0.80, 95% CI 0.64 to 0.99; 2 trials, n=323). When the third trial (including older and more seriously affected patients) was added, the overall treatment effect was reduced but still significant (HR 0.84, 95% CI 0.698 to 0.997; 3 trials, n=1282). This represented a 9% gain in the probability of surviving one year (49% in the placebo vs. 58% in the riluzole group), and increased median survival from 11.8 to 14.8 months. There was a small beneficial effect on both bulbar and limb function, but not on muscle strength. A three-fold increase in serum alanine transferase was more frequent in riluzole-treated patients than controls in the combined data (MD 2.62, 95% CI 1.59 to 4.31).

Comment: The quality of evidence is downgraded by inconsistency (heterogeneity in patients and results).

    References

    • Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2012;3:CD001447. [PubMed]

Primary/Secondary Keywords